Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Learn more about:
Related Clinical Trial
Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Official Title

A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities

Brief Summary

      The purpose of this study is to compare the safety and effectiveness of fenofibrate and
      pravastatin in treating HIV-positive patients who have abnormal levels of fat (lipids) in the
      blood.

      Increased lipids in the blood associated with HIV infection and anti-HIV drugs is a growing
      problem. The drugs used in this study are known to reduce certain lipids, but little is known
      about their safety and effectiveness. This study will see if one of the drugs is safer and
      more effective than the other, or if combining the drugs is the safest and most effective way
      to lower lipids. This study has been changed. On June 26, 2001, this study was reviewed by
      the Data and Safety Monitoring Board (DSMB). The DSMB is an independent board monitoring the
      progress of the study. The review showed that neither pravastatin nor fenofibrate alone were
      effective in reaching all the cholesterol and triglyceride goals. There were no safety
      concerns. It is not known if the combination of fenofibrate and pravastatin is effective and
      safe. Therefore, it is important to continue this study.
    

Detailed Description

      Lipid disorders associated with HIV infection and antiretroviral therapy are of growing
      concern. There is little information available on the safety and efficacy of statins or
      fibrates in the treatment of HIV-associated hyperlipidemias. Fenofibrate and pravastatin both
      are able to reduce low-density lipoproteins (LDL) and triglycerides (TG), but it is unclear
      whether one therapy will be more effective than the other, or if combination therapy will be
      needed to achieve desirable reductions in both LDL and TG. [AS PER AMENDMENT 12/13/01: The
      NIAID HIV Therapeutic Trials Data and Safety Monitoring Board (DSMB) met June 26, 2001 to
      review the interim results. The interim monitoring plan for this study states that accrual
      into either single-agent therapy arm should stop if the response rate failed to meet a
      pre-specified minimum at the time of interim review. The DSMB found that this stopping
      criterion was met for each single-therapy arm. The DSMB recommended that patients currently
      on single-agent therapy be offered the opportunity to initiate dual-agent therapy, regardless
      of time on study. There were no safety concerns.]

      Patients are randomized to either Arm A or Arm B and stratified by gender, TG level, and
      number of cardiovascular risk factors. Patients add daily fenofibrate (Arm A) or pravastatin
      (Arm B) to their antiretroviral therapy for 48 weeks. Evaluations at Week 12 determine LDL,
      TG, and high-density lipid (HDL) levels. Patients who achieve clinical goals for these levels
      stay on the drug for the rest of the study. Patients who do not achieve the goals by Week 12
      receive a combination of pravastatin and fenofibrate for the rest of the study. At regular
      clinic visits, patients have physical exams and are questioned about their medications, diet,
      and exercise. Blood samples are drawn for clinical evaluations, including lipid profiles and
      HIV-1 RNA monitoring. [AS PER AMENDMENT 12/13/01: On June 26, 2001, the DSMB reviewed interim
      results and determined that the response rates for both arms met the stopping rule for
      futility. As a result, all patients who were currently on single-agent therapy were offered
      the opportunity to initiate dual-agent therapy regardless of time on study. No additional
      accrual was sought; however, exceptions were made for patients who were in screening at the
      time of the DSMB review. These patients were given the option of starting single- or
      dual-agent therapy. The DSMB recommended that all patients on dual-agent therapy be followed
      for 32 weeks to obtain additional safety and efficacy data. Further endpoints will be
      analyzed after Week 12 of single-agent therapy or Week 32 of dual-agent therapy.]
    

Study Phase

Phase 3

Study Type

Interventional




Condition

HIV Infections

Intervention

Pravastatin sodium


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

630


Completion Date

May 2003


Eligibility Criteria

        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Are at least 18 years old.

          -  Are on a lipid-lowering diet based on the patient's statement and have been exercising
             for at least 30 days before being screened for the study. Patients will be asked if
             they were counseled by their health care provider. The lipid-lowering diet and
             exercise program do not have to be prescribed by a physician.

          -  Have a triglyceride (TG) level of at least 200 mg/dl and low-density lipoprotein (LDL)
             level of at least 130 mg/dl after fasting for 8 to 12 hours.

          -  Have been treated with anti-HIV drugs for more than 6 months. Patients must be taking
             the anti-HIV drugs regularly for at least 4 weeks before they enter the study.
             Patients must be taking anti-HIV drugs regularly for at least 8 weeks if they have
             changed from taking protease inhibitor (PI) anti-HIV drugs to non-PI anti-HIV drugs.
             Any combination without a PI must lower the patient's HIV viral levels, as determined
             by the patient's physician.

          -  Are willing, if able to become pregnant, to use 2 reliable types of birth control
             while taking the study drug(s) and for 1 month after stopping the drug(s).

          -  Have a negative pregnancy test.

          -  (This reflects a change in inclusion requirements.)

        Exclusion Criteria

        Patients will not be eligible for the study if they:

          -  Have a history of heart disease.

          -  Have uncontrolled high blood pressure within 4 weeks of study entry.

          -  Have liver disease.

          -  Have gall bladder disease or symptoms within 3 months prior to study entry or symptoms
             of gallstones.

          -  Had surgery to remove their gallbladder within 3 months prior to study entry.

          -  Have diabetes requiring drug treatment or diabetes not controlled by diet.

          -  Have hypothyroidism (low thyroid activity).

          -  Are allergic or sensitive to the study drug(s) or to other lipid-lowering drugs.

          -  Have rhabdomyolysis (a muscle disease).

          -  Have taken any prescription or non-prescription lipid-lowering drug within 14 days
             prior to study entry or for over 24 weeks in the past.

          -  Take prescription lipid-lowering agents, other than those given by the study, and
             non-prescription lipid-lowering agents such as garlic supplements.

          -  Have failed previous statin or fibrate therapy (after 24 weeks of treatment) or have
             had side effects from these drugs.

          -  Receive or have received (within 14 days of study entry) treatment not approved by the
             FDA. Anti-HIV medications and immune-based treatments not approved by the FDA may be
             allowed on a case-by-case basis with the approval of the protocol team.

          -  Were given systemic chemotherapy for cancer other than Kaposi's sarcoma (KS).

          -  Were given radiation therapy within 30 days of study entry.

          -  Take drugs that increase risk of muscle disease (such as cyclosporine, erythromycin,
             itraconazole, and ketoconazole), within 14 days of study entry.

          -  Take or have taken levothyroxine and liothyronine for hypothyroidism.

          -  Take high doses of testosterone.

          -  Take creatine monophosphate or drugs that affect the immune system, within 30 days of
             study entry.

          -  Abuse drugs or alcohol, and the doctor thinks this may interfere with the study.

          -  Are pregnant or breast-feeding.

          -  Had a scheduled anti-HIV treatment withdrawal prior to study entry.

          -  (This reflects a change in exclusion requirements.)
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Judith Aberg, , 

Location Countries

Puerto Rico

Location Countries

Puerto Rico

Administrative Informations


NCT ID

NCT00006412

Organization ID

A5087

Secondary IDs

10917

Responsible Party

Sponsor

Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)


Study Sponsor

Judith Aberg, Study Chair, 


Verification Date

July 2013